Table 4.
Univariate and multivariate Cox proportional hazards models of mortality among AIDS-defining and non-AIDS defining cancer at cancer diagnosis.
| No. of deaths | HR (95% CI) | P value | Adjusted HR (95% CI)a | P value | |
|---|---|---|---|---|---|
| AIDS-defining cancer | |||||
| Age group (years) | |||||
| <40 | 53 | 1.0 (ref) | – | 1.0 (ref) | – |
| 40–49 | 24 | 0.94 (0.58–1.52) | 0.79 | 1.05 (0.63–1.76) | 0.84 |
| ≥50 | 9 | 1.39 (0.66–2.95) | 0.38 | 2.21 (1.00–4.89) | 0.05 |
| Gender | |||||
| Male | 64 | 1.0 (ref) | – | 1.0 (ref) | – |
| Female | 22 | 1.30 (0.79–2.14) | 0.30 | 1.96 (1.12–3.48) | 0.02 |
| Race | |||||
| White | 24 | 1.0 (ref) | – | 1.0 (ref) | – |
| Black | 62 | 1.35 (0.83–2.19) | 0.22 | 1.15 (0.68–1.93) | 0.60 |
| Injection drug use | 23 | 1.00 (0.61–1.63) | 1.00 | ||
| HIV-1 RNA <400 copies/mlb | 17 | 0.48 (0.22–1.02) | 0.06 | ||
| CD4 cell count group(cells/μl) | |||||
| >350 | 8 | 1.0 (ref) | – | 1.0 (ref) | – |
| 201–350 | 4 | 0.72 (0.22–2.40) | 0.60 | 0.83 (0.25–2.79) | 0.76 |
| 51–200 | 24 | 1.84 (0.82–4.10) | 0.14 | 2.26 (0.98–5.23) | 0.06 |
| ≤50 | 47 | 2.71 (1.27–5.75) | 0.01 | 4.02 (1.75–9.26) | 0.001 |
| Non-AIDS-defining cancer | |||||
| Age group (years) | |||||
| <40 | 9 | 1.0 (ref) | – | 1.0 (ref) | – |
| 40–49 | 33 | 1.70 (0.78–3.72) | 0.18 | 1.75 (0.77–3.99) | 0.18 |
| ≥50 | 30 | 1.41 (0.64–3.10) | 0.39 | 1.67 (0.71–3.90) | 0.24 |
| Gender | |||||
| Male | 54 | 1.0 (ref) | – | 1.0 (ref) | – |
| Female | 18 | 1.68 (0.96–2.95) | 0.07 | 1.48 (0.81–2.73) | 0.21 |
| Race | |||||
| White | 13 | 1.0 (ref) | – | 1.0 (ref) | – |
| Black | 59 | 1.96 (1.07–3.60) | 0.03 | 1.76 (0.95–3.29) | 0.07 |
| History of injection drug use | 39 | 1.30 (0.81–2.09) | 0.28 | ||
| HIV-1 RNA <400 copies/mlb | 23 | 0.57 (0.34–0.95) | 0.03 | ||
| CD4 cell count group (cells/μl) | |||||
| >350 | 28 | 1.0 (ref) | – | 1.0 (ref) | – |
| 201–350 | 17 | 0.75 (0.41–1.38) | 0.36 | 0.76 (0.41–1.39) | 0.37 |
| 51–200 | 19 | 1.17 (0.64–2.14) | 0.62 | 1.33 (0.70–2.52) | 0.38 |
| ≤50 | 8 | 1.11 (0.48–2.58) | 0.80 | 1.21 (0.50–2.90) | 0.67 |
HR, hazards ratio; CI, confidence interval.
Adjusted HR from multivariate model that included age, gender, race, and CD4 cell count at the time of cancer diagnosis. Multivariate models did not include mean values of variables.
Reference group are those with HIV-1 RNA ≥400 copies/ml at the time of cancer diagnosis.